About OceansBIo
OceansBIo is a company based in Changwon (South Korea) founded in 2021. OceansBIo offers products and services including TaVNS. OceansBIo operates in a competitive market with competitors including NeuroPace, Cadence Neuroscience, Engage Therapeutics, NightWatch and Cyberonics, among others.
- Headquarter Changwon, South Korea
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website oceansbio.com
- Legal Name Oceansbio Co., Ltd.
- InvestorsSNU Holdings
& 2 more
Associated legal entities of OceansBIo
OceansBIo operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of OceansBIo
OceansBIo offers a comprehensive portfolio of products and services, including TaVNS.
Device that delivers impulses to vagus nerve for neurological relief.
Funding Insights of OceansBIo
- Total Rounds 1
- Investors Count 3
All 1 funding rounds of OceansBIo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | – | Series A | – | – |
3 investors in total: 3 institutional.
Investors in OceansBIo
OceansBIo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SNU Holdings, Korea Credit Guarantee Fund and D.CAMP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | snuholdings.com | - | |
- | – | dcamp.kr | - | |
- | – | kodit.co.kr | - |
Investor details for OceansBIo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of OceansBIo
OceansBIo is a publicly listed company on the KRX with ticker symbol 332190 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Jan 2025
- Listed onKRX: 332190
- Listed entityOceansBio Co., Ltd.
- Exchange sectorTechnology services
- ISINKR7332190008
- Share price2,890.00 KRW (-3.02% on the day) · 2026-10-08
- Volume (last session)331
Timeline of OceansBIo
3 dated milestones of OceansBIo across 4 years, from founding to its latest funding, stage changes and deals.
- Founded OceansBIo is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
Competitors of OceansBIo
OceansBIo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuroPace, Cadence Neuroscience, Engage Therapeutics, NightWatch and Cyberonics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neuropace.com | 1997 | United States | $263.56M | 184 | Implantable neurostimulation systems for epilepsy treatment are developed. | |
| cadenceneuro.com | 2016 | Redmond, United States | $41.03M | – | Medical devices for treating neurological disorders like epilepsy are developed. | |
| engagetherapeutics.com | 2017 | Summit, United States | $30.6M | – | Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | |
| nightwatchepilepsy.com | 2013 | Leiden, Netherlands | – | – | Wearable armbands for detecting epileptic seizures during sleep are offered. | |
| cyberonics.com | 1987 | Houston, United States | – | 660 | Vagus nerve stimulation therapy is developed for epilepsy and depression. | |
| cerbomed.de | 2005 | Erlangen, Germany | $2.6M | – | Neuro-therapy solutions are developed for drug-resistant epilepsies and disorders. | |
| neurolinkmedical.com | 2007 | San Antonio, United States | $3.88M | – | Develops drug-device combinations for epilepsy treatment. | |
| precisis.de | 2002 | Heidelberg, Germany | – | 14 | Devices and tools for neurological surgery are developed. |
Detailed competitors of OceansBIo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OceansBIo
The website of OceansBIo (oceansbio.com) receives about 1.3K visits a month.
- Monthly visits1.3K
Similar companies to OceansBIo
10 companies that operate in the same segment as OceansBIo (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OceansBIo
OceansBIo was founded in 2021 and raised its 1st funding round 2 years after it was founded.
OceansBIo is headquartered in Changwon, South Korea. It is registered at Changwon, Gyeongsangnam-do, South Korea.
Founded in 2021 and based in Changwon, South Korea, electroceutical devices for epilepsy treatment are developed by the company. Implantable human devices are created using AI technology within the medical device sector. Operations focus on advancing therapeutic solutions for neurological conditions, with emphasis on precise, AI-driven interventions tailored to epilepsy management.
OceansBIo's top competitors include NeuroPace, Engage Therapeutics and Cyberonics.
OceansBIo offers TaVNS.
Yes, OceansBIo is publicly traded on KRX under the ticker symbol 332190.
OceansBIo has 3 investors. Key investors include SNU Holdings, Korea Credit Guarantee Fund, and D.CAMP.
OceansBIo operates through ,.